SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.35 +0.18 (+0.45%)
At close: 4:02PM EST
People also watch
NVS GSK AZN LLY NVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 40.17
Open 40.42
Bid 0.00 x
Ask 0.00 x
Day's Range 40.23 - 40.58
52 Week Range 36.81 - 44.50
Volume 988,291
Avg. Volume 2,203,803
Market Cap 100.95B
Beta 0.83
PE Ratio (TTM) 23.45
EPS (TTM) 1.72
Earnings Date N/A
Dividend & Yield 1.66 (4.12%)
Ex-Dividend Date N/A
1y Target Est 48.67
Trade prices are not sourced from all markets
  • Reuters 2 days ago

    Sanofi's M&A misses frustrate some investors in drugmaker

    PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.

  • MannKind Has a New Plan, but Will It Work?
    Motley Fool 4 days ago

    MannKind Has a New Plan, but Will It Work?

    MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?

  • Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
    Zacks 4 days ago

    Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

    Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

  • Reuters 4 days ago

    Drugmakers in Davos shift focus to chronic diseases of poor

    Two decades after they were spurred into action to tackle AIDS in Africa, global drugmakers said on Wednesday they would invest an initial $50 million over three years to fight cancer and other non-communicable diseases in poor countries. Twenty-two companies, including Pfizer, Merck , Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank. The so-called Access Accelerated initiative was announced at the World Economic Forum in Davos and aims to improve both treatment and prevention.

  • Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
    Investor's Business Daily 5 days ago

    Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad

    Regeneron and Sanofi argue Amgen's patents covering LDL-buster Repatha are too broad.

  • Key FDA Events to Watch Out for in Q1
    Zacks 5 days ago

    Key FDA Events to Watch Out for in Q1

    Two important regulatory events scheduled in the first quarter of 2017.

  • Forbes 6 days ago

    5 Trump-Proof Pharma Dividends Up To 5.3%

    Trump hasn’t yet entered the Oval Office, but he’s already showing an uncanny knack for creating quick stock dips with just a sentence or two.

  • Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016
    Motley Fool 7 days ago

    Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016

    Issues with programs developed in collaboration with Sanofi kept the otherwise promising biotech stock depressed.

  • Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
    Investor's Business Daily 9 days ago

    Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink

    Amgen will likely triumph in a patent battle with Regeneron and Sanofi, Leerink says.

  • Investopedia 9 days ago

    Sanofi, ImmuNext Sign $500M Autoimmune Drug Pact

    Sanofi and ImmuNext signed a drug development deal worth up to $500 million.